Last Updated: May 12, 2026

Claims for Patent: 8,470,777

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,470,777

Title:	Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
Abstract:	The present invention relates to a method to increase oligodendrocytes and oligodendrocyte precursor cells through administration of prolactin or a prolactin inducing agent.
Inventor(s):	Gregg; Christopher (Cambridge, MA), Weiss; Samuel (Calgary, CA)
Assignee:	Stem Cell Therapeutics Corp. (Calgary, Alberta, CA)
Application Number:	13/102,635
Patent Claims:	1. A method for reducing a symptom of a demyelinating disease in a subject, the method comprising selecting a subject with or suspected of having a demyelinating disease, and administering to the subject an effective amount of a prolactin or a prolactin releasing peptide. 2. The method of claim 1, wherein the demyelinating disease is multiple sclerosis. 3. The method of claim 1, further comprising administering to the subject a biological agent selected from the group consisting of epidermal growth (EGF), fibroblast growth factor (FGF), transforming growth factor alpha (TGF.alpha.), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), platelet-derived growth factor (PDGF), estrogen, ovarian hormone, human chorionic gonadotropin (hCG), insulin-like growth factor-1, and triiodothyrionine. 4. The method of claim 3, wherein the biological agent is hCG. 5. The method of claim 3, wherein the biological agent is PDGF. 6. The method of claim 3, wherein the biological agent is administered before the prolactin or prolactin releasing peptide. 7. The method of claim 3, wherein the biological agent is administered after the prolactin or prolactin releasing peptide. 8. The method of claim 3, wherein the biological agent is administered before and after the prolactin or prolactin releasing peptide. 9. A method of reducing a symptom of a disease or condition associated with demyelination in a subject, the method comprising selecting a subject with or suspected of having a disease or condition associated with demyelination and administering to the subject an effective amount of a prolactin or a prolactin releasing peptide. 10. The method of claim 9, wherein the disease or condition associated with demyelination is selected from the group consisting of multiple sclerosis, acute disseminated encephalomyelitis, diffuse cerebral sclerosis, necrotizing hemorrhagic encephalitis, leukodystrophies, stroke, spinal cord injury, bipolar disorder, acute brain injury, and dementia. 11. The method of claim 9, further comprising administering to the subject a biological agent selected from the group consisting of epidermal growth (EGF), fibroblast growth factor (FGF), transforming growth factor alpha (TGF.alpha.), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), platelet-derived growth factor (PDGF), estrogen, ovarian hormone, human chorionic gonadotropin (hCG), insulin-like growth factor-1, and triiodothyrionine. 12. The method of claim 11, wherein the biological agent is hCG. 13. The method of claim 11, wherein the biological agent is PDGF. 14. The method of claim 11, wherein the biological agent is administered before the prolactin or prolactin releasing peptide. 15. The method of claim 11, wherein the biological agent is administered after the prolactin or prolactin releasing peptide. 16. The method of claim 11, wherein the biological agent is administered before and after the prolactin or prolactin releasing peptide.

Details for Patent 8,470,777

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	⤷ Start Trial	2031-05-06
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	⤷ Start Trial	2031-05-06
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	⤷ Start Trial	2031-05-06
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	⤷ Start Trial	2031-05-06
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974	⤷ Start Trial	2031-05-06
Ferring Pharmaceuticals Inc.	A.P.L.	chorionic gonadotropin	For Injection	017055	December 13, 1974	⤷ Start Trial	2031-05-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.